Ord Minnett analyst Tom Godfrey maintained a Buy rating on Australian Clinical Labs Ltd (ACL – Research Report) today and set a price target of A$3.35. The company’s shares opened today at A$2.96.

Australian Clinical Labs (ACL) has been ordered to pay AUD5.8 million for breach of the Privacy Act 1988 (Cth) (Privacy Act) following a 2022 cyber incident which ...

Australian Clinical Labs recently reported half-year 2025 results showing slightly lower revenue of A$365.79 million and net income of A$5.57 million, while also declaring a fully franked interim ...

The Federal Court has ordered Australian Clinical Labs (ACL) to pay AU$5.8 million in civil penalties following a 2022 data breach involving its then-newly acquired Medlab Pathology business. The ...

In a report released on January 29, Craig Wong-Pan from RBC Capital maintained a Buy rating on Australian Clinical Labs Ltd (ACL – Research Report), with a price target of A$4.25. The company’s shares ...

Most readers would already know that Australian Clinical Labs' (ASX:ACL) stock increased by 5.0% over the past three months. As most would know, long-term fundamentals have a strong correlation with ...

Scientists fear for Geelong patients’ safety after Australian Clinical Labs informed their union of further cuts, in what has been slammed as a “diabolically bad” decision for public health. ACL will ...

Melinda McGrath founded Tasmanian Medical Laboratories. Ms. McGrath also currently works at Clinical Laboratories Pty Ltd., as Chief Executive Officer & Executive Director from 2015, Australian ...

About Australian Clinical Labs Ltd. Australian Clinical Labs Ltd. engages in the provision of pathology services. It operates through the Pathology segment. The Pathology segment includes ...

About Australian Clinical Labs Ltd. Australian Clinical Labs Ltd. engages in the provision of pathology services. It operates through the Pathology segment. The Pathology segment includes ...